CSIMarket Company Name, Ticker, Industry, else..
 
Acrivon Therapeutics Inc   (NASDAQ: ACRV)
 
Price: $1.7000 $-0.13 -7.104%
Day's High: $1.899999976158142 Week Perf: -16.67 %
Day's Low: $ 1.70 30 Day Perf: -17.07 %
Volume (M): 764,280 52 Wk High: $ 3.56
Volume (M$): $ 0 52 Wk Avg: $1.87
Open: $1.85 52 Wk Low: $1.27



 Market Capitalization (Millions $) 71
 Shares Outstanding (Millions) 42
 Employees 76
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -74
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 1

Business Description


Acrivon Therapeutics Inc is a pharmaceutical company that focuses on developing innovative therapies for various diseases and medical conditions. The company is dedicated to improving patient outcomes by utilizing cutting-edge technologies and advanced research methodologies. Acrivon Therapeutics Inc aims to address unmet medical needs and deliver effective treatments through their pipeline of novel drugs. Their mission is to make a significant impact in healthcare by providing breakthrough therapies and improving the overall quality of life for patients.


   Company Address: 480 Arsenal Way Watertown 2472 MA
   Company Phone Number: 207-8979   Stock Exchange / Ticker: NASDAQ ACRV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -0.6%    
MDGL   -3.21%    
NRIX   -4.23%    
RYTM   -3.02%    
SUPN   -1.64%    
ZYME   -3.35%    
• View Complete Report
   



Clinical Study

Innovative Cancer Therapy Acrivon Therapeutics Embarks on Phase 1 Trial with Advanced WEE1/PKMYT1 Inhibito...

Published Fri, Oct 11 2024 12:00 PM UTC

In the dynamic field of cancer therapeutics, pioneering research and early-stage clinical trials are crucial steps in the development of novel treatment options. Acrivon Therapeutics, a biotechnology company committed to precision oncology, has recently announced a significant milestone in its research endeavors. The company has initiated the first patient dosing in its Phas...
Clinical Study

Acrivon Therapeutics Pioneering Precision Medicine with Promising Trial Results and New Drug Development

Published Sat, Sep 14 2024 7:10 AM UTC

Acrivon Therapeutics: Positive Progress Amid Market VolatilityAcrivon Therapeutics, Inc. a clinical-stage precision medicine company based in Watertown, Massachusetts, has made notable strides in cancer treatment and drug development, as presented at the recent European Society for Medical Oncology (ESMO) conference. The company s advancements largely stem from its propriet...
Clinical Study

for this Acrivon Therapeutics Unveils Robust Clinical Success and Innovative Pipeline at Upcoming Investor Even...

Published Mon, Sep 9 2024 11:00 AM UTC

Acrivon Therapeutics Announces Groundbreaking Developments: Positive Phase 2 Data and Promising Pipeline Progress Webcast Investor Event to Highlight Encouraging Clinical Data and Advancements in Predictive Precision Proteomics Acrivon Therapeutics is set to host a virtual investor event on September 14, 2024, at 9:00 a.m. ET to discuss the positive Phase 2 clinical data of...
Clinical Study

Acrivon Therapeutics' ACR-368 Shows Promising Results in Ovarian and Endometrial Cancers

Published Wed, Apr 24 2024 8:01 PM UTC

Acrivon Therapeutics, a leading pharmaceutical company, presented initial positive clinical data for their investigational drug ACR-368 and highlighted progress in their pipeline program at a recent Corporate R&D event. The data showcased the efficacy of ACR-368 in treating ovarian and endometrial cancers, as well as the validation of their AP3 patient selection platform and...
Clinical Study

Acrivon Therapeutics Unveils Breakthrough Precision Proteomics Platform at AACR Annual Meeting

Published Wed, Apr 10 2024 12:00 PM UTC

Acrivon Therapeutics, a leading biopharmaceutical company focused on innovative cancer therapies, recently presented groundbreaking data at the prestigious American Association for Cancer Research (AACR) Annual Meeting. The company showcased the potential of their proprietary technology, Acrivon Predictive Precision Proteomics (AP3), in accelerating the discovery of novel ca...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.82
PEG (TTM) -

Financial Strength Current
Quick Ratio 104.48
Working Capital Ratio 106.26
Leverage Ratio (MRQ) 0.14
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.88 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 2.15 $
Book Value 2.07 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -976,645
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.